DUBLIN--(BUSINESS WIRE)--Mar 25, 2020--

The vaccines market analysis considers sales from both prophylactic vaccines and therapeutic vaccine types. Our analysis also considers the sales of vaccines in Asia, Europe, North America, and ROW. In 2019, the prophylactic vaccines segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high safety and efficacy will play a significant role in the prophylactic vaccines segment to maintain its market position.

Also, our global vaccines market report looks at factors such as increased funding for vaccine development and new vaccine launches, approval of vaccines and strong pipeline, and increasing use of adjuvants in vaccines. However, high costs of vaccine research, development, and manufacturing, product recalls, and safety concerns may hamper the growth of the vaccines industry over the forecast period.

Companies Mentioned

  • Bavarian Nordic AS
  • CSL Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi

Global Vaccines Market: Overview

Increasing the use of adjuvants in vaccines

With the increasing use of vaccines to treat and prevent life-threatening diseases, vendors are focusing on strategies for the development of effective new vaccines and usage of suitable adjuvants. They work by improving the humoral and cell-mediated immune response to vaccine antigens. The rise of the use of adjuvants, such as immunologic adjuvants, in new vaccines has increased to combat emerging new pathogens and re-emerging old pathogens. The demand for such vaccines is also high because of their long-lasting protective immune response. This will lead to the expansion of the global vaccines market at a CAGR of almost 7% during the forecast period.

Development of nanoparticle vaccines

The nanoparticle-based vaccines have higher immunization and targeted delivery attributes. This has led the vendors to invest in R&D of nanoparticle vaccines due to the ongoing research to develop vaccines against specific diseases. For instance, prophylactic vaccines are associated with the risk of regaining their pathogenicity under certain immunocompromised conditions. This limitation can be overcome by using nanoparticle vaccines. Such development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global vaccines market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading vaccines manufacturers, that include Bavarian Nordic AS, CSL Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novavax Inc., Pfizer Inc., and Sanofi

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. SCOPE OF THE REPORT

  • Preface
  • Currency conversion rates for US$

3. MARKET LANDSCAPE

  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis

4. MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024

5. FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

6. MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Prophylactic vaccines - Market size and forecast 2019-2024
  • Therapeutic vaccines - Market size and forecast 2019-2024
  • Market opportunity by type

7. CUSTOMER LANDSCAPE

8. GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

9. DECISION FRAMEWORK

10. DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

11. MARKET TRENDS

  • R&D of novel vaccines
  • Development of nanoparticle vaccines
  • Advancement in vaccine delivery system

12. VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

13. VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors

14. APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/r/xi0sv

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 03/25/2020 11:08 AM/DISC: 03/25/2020 11:08 AM

Copyright Business Wire 2020.